Akari Therapeutics Appoints Dr. Olga Anczukow to Scientific Advisory Board
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy AKTX?
Akari Therapeutics announced the appointment of Olga Anczukow, Ph.D. to its Scientific Advisory Board. She currently serves as an Associate Professor at The Jackson Laboratory for Genomic Medicine and a Co-Program Leader at the NCI-designated Jackson Laboratory Cancer Center, and holds a joint faculty appointment at University of Connecticut School of Medicine, where she leads a multidisciplinary research program focused on elucidating the mechanisms by which alternative RNA splicing, a fundamental process in gene expression regulation, becomes misregulated in cancer and drives tumor initiation, progression, metastasis, and therapeutic resistance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AKTX
Wall Street analysts forecast AKTX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.236
Low
1.00
Averages
3.33
High
7.00
Current: 0.236
Low
1.00
Averages
3.33
High
7.00
About AKTX
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Akari Therapeutics Appoints New Scientific Advisor to Advance AKTX-101
- New Scientific Advisor: Akari Therapeutics has appointed Dr. Prafulla Gokhale to its Scientific Advisory Board, leveraging his extensive experience in experimental therapeutics and translational oncology to enhance the development of AKTX-101, which is expected to improve the likelihood of successful product advancement.
- Clinical Trial Advancement: Dr. Gokhale's expertise comes at a pivotal time as AKTX-101 progresses toward clinical trials, and his insights will help ensure the drug enters the clinic with a focused, data-driven high-impact program to optimize therapeutic outcomes.
- Unique Drug Mechanism: The novel PH1 payload of AKTX-101 targets RNA splicing, offering a different mechanism compared to traditional antibody-drug conjugates, potentially disrupting tumor survival pathways while enhancing immune system engagement.
- Future Outlook: Akari aims to initiate its First-In-Human trial for AKTX-101 by late 2026 to early 2027, and Dr. Gokhale's involvement is expected to accelerate this process, bolstering the company's competitiveness in oncology drug development.
See More
Akari Therapeutics to Present at Biocom Global Partnering Conference
- Presentation Schedule: Akari Therapeutics' CEO Abizer Gaslightwala will present at the Biocom Global Partnering & Investor Conference on February 25, 2026, at 11:00 AM PST in San Diego, CA, showcasing the company's advancements in antibody-drug conjugates (ADCs), which is expected to attract investor interest and enhance the company's visibility.
- Innovative Drug Development: The company's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a unique PH1 payload designed to modulate RNA splicing, inducing cancer cell death, with significant anti-tumor activity demonstrated in preclinical animal models, potentially offering new hope in cancer treatment.
- Clinical Trial Plans: Akari has initiated IND enabling studies for AKTX-101, aiming to start its First-In-Human trial by late 2026 or early 2027, marking a significant milestone in the company's oncology drug development and potentially laying the groundwork for future market introduction.
- Multiple Target Potential: AKTX-101 has shown prolonged survival potential when used in combination with checkpoint inhibitors and demonstrates strong activity against cancer cells with key oncogenic drivers, providing a broad application prospect across various cancer types.
See More
Akari Therapeutics Highlights 2025 Progress, Plans First-in-Human Trials in 2026
- Strategic Partnership: Akari Therapeutics has established a strategic manufacturing partnership with WuXi Biologics to support its clinical trial preparations for 2026, marking a significant advancement in the company's oncology drug development.
- Innovative Drug Platform: The company is leveraging its unique PH1 payload platform to develop next-generation antibody-drug conjugates (ADCs), which have demonstrated compelling preclinical efficacy and safety, potentially transforming cancer treatment paradigms.
- Clinical Trial Plans: Akari plans to initiate its First-in-Human trial by the end of 2026, aiming to validate the efficacy of its lead candidate AKTX-101, which is expected to create new growth opportunities for the company.
- Market Potential: AKTX-101 targets the Trop2 receptor on cancer cells with a proprietary linker, anticipated to significantly enhance therapeutic efficacy and potentially synergize with checkpoint inhibitors, thereby strengthening the company's competitive position in the market.
See More
Akari Therapeutics Presents ADC Platform and 2026 Strategic Priorities at Biotech Showcase
- Strategic Presentation: Akari Therapeutics' CEO Abizer Gaslightwala will present the company's antibody-drug conjugate (ADC) platform and 2026 strategic priorities at the Biotech Showcase on January 13, 2026, aiming to attract investor interest in its innovative drug development.
- Innovative Drug Development: Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells with its unique PH1 payload, showing significant effects in inducing cancer cell death and activating the immune system in preclinical studies, potentially offering new hope in cancer treatment.
- Clinical Trial Plans: The company has initiated IND enabling studies for AKTX-101, with plans to start its First-In-Human trial by late 2026 or early 2027, marking a significant step in its development and market potential in oncology.
- Multipronged Target Strategy: In addition to AKTX-101, Akari is advancing AKTX-102, an ADC targeting a novel antigen highly relevant in gastrointestinal and lung cancers, showcasing the company's broad pipeline and research capabilities across multiple cancer treatment areas.
See More
Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%
- FDA Approval: Vanda Pharmaceuticals' NEREUS (tradipitant) has received FDA approval for the prevention of motion-induced vomiting in adults, marking a significant advancement in the company's neuropharmaceutical portfolio and is expected to drive future sales growth.
- Stock Surge: Following the FDA approval announcement, Vanda's shares jumped 17.5% to $8.26 in pre-market trading, reflecting strong market confidence in the new drug's potential and likely attracting increased investor interest.
- Market Outlook: The approval of NEREUS not only opens new market opportunities for Vanda Pharmaceuticals but also enhances its market share in the competitive antiemetic drug sector, strengthening the company's long-term profitability prospects.
- Investor Confidence: This FDA approval boosts investor expectations for Vanda's future performance, potentially prompting more institutional investors to reassess their portfolios, further driving the stock price upward.
See More
Akari Therapeutics Advances Novel Antibody Drug Conjugates with Significant Achievements in 2025
- Strategic Milestones: In 2025, Akari Therapeutics made significant strides in the antibody-drug conjugate (ADC) space, particularly with its PH1 payload-based ADC designed to overcome limitations of existing therapies, thereby offering more effective treatment options for cancer patients.
- Lead Program Progress: AKTX-101 achieved notable results in 2025, especially demonstrating strong anti-tumor activity in pancreatic and prostate cancer models, which is expected to lay a solid foundation for clinical trials and enhance the company's competitiveness in cancer treatment.
- GMP Manufacturing Partnership: The collaboration with WuXi XDC marks Akari's transition from a preclinical discovery company to a clinical biotechnology player, ensuring the production of high-quality clinical products to support upcoming trials in 2026.
- Intellectual Property Enhancement: Akari filed three new patents in 2025 to protect the uniqueness of its PH1 payload, further solidifying its market position in the ADC field and providing legal safeguards for future R&D efforts.
See More
Akari Therapeutics Appoints New Scientific Advisor to Advance AKTX-101
- New Scientific Advisor: Akari Therapeutics has appointed Dr. Prafulla Gokhale to its Scientific Advisory Board, leveraging his extensive experience in experimental therapeutics and translational oncology to enhance the development of AKTX-101, which is expected to improve the likelihood of successful product advancement.
- Clinical Trial Advancement: Dr. Gokhale's expertise comes at a pivotal time as AKTX-101 progresses toward clinical trials, and his insights will help ensure the drug enters the clinic with a focused, data-driven high-impact program to optimize therapeutic outcomes.
- Unique Drug Mechanism: The novel PH1 payload of AKTX-101 targets RNA splicing, offering a different mechanism compared to traditional antibody-drug conjugates, potentially disrupting tumor survival pathways while enhancing immune system engagement.
- Future Outlook: Akari aims to initiate its First-In-Human trial for AKTX-101 by late 2026 to early 2027, and Dr. Gokhale's involvement is expected to accelerate this process, bolstering the company's competitiveness in oncology drug development.
See More
Akari Therapeutics to Present at Biocom Global Partnering Conference
- Presentation Schedule: Akari Therapeutics' CEO Abizer Gaslightwala will present at the Biocom Global Partnering & Investor Conference on February 25, 2026, at 11:00 AM PST in San Diego, CA, showcasing the company's advancements in antibody-drug conjugates (ADCs), which is expected to attract investor interest and enhance the company's visibility.
- Innovative Drug Development: The company's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a unique PH1 payload designed to modulate RNA splicing, inducing cancer cell death, with significant anti-tumor activity demonstrated in preclinical animal models, potentially offering new hope in cancer treatment.
- Clinical Trial Plans: Akari has initiated IND enabling studies for AKTX-101, aiming to start its First-In-Human trial by late 2026 or early 2027, marking a significant milestone in the company's oncology drug development and potentially laying the groundwork for future market introduction.
- Multiple Target Potential: AKTX-101 has shown prolonged survival potential when used in combination with checkpoint inhibitors and demonstrates strong activity against cancer cells with key oncogenic drivers, providing a broad application prospect across various cancer types.
See More
Akari Therapeutics Highlights 2025 Progress, Plans First-in-Human Trials in 2026
- Strategic Partnership: Akari Therapeutics has established a strategic manufacturing partnership with WuXi Biologics to support its clinical trial preparations for 2026, marking a significant advancement in the company's oncology drug development.
- Innovative Drug Platform: The company is leveraging its unique PH1 payload platform to develop next-generation antibody-drug conjugates (ADCs), which have demonstrated compelling preclinical efficacy and safety, potentially transforming cancer treatment paradigms.
- Clinical Trial Plans: Akari plans to initiate its First-in-Human trial by the end of 2026, aiming to validate the efficacy of its lead candidate AKTX-101, which is expected to create new growth opportunities for the company.
- Market Potential: AKTX-101 targets the Trop2 receptor on cancer cells with a proprietary linker, anticipated to significantly enhance therapeutic efficacy and potentially synergize with checkpoint inhibitors, thereby strengthening the company's competitive position in the market.
See More
Akari Therapeutics Presents ADC Platform and 2026 Strategic Priorities at Biotech Showcase
- Strategic Presentation: Akari Therapeutics' CEO Abizer Gaslightwala will present the company's antibody-drug conjugate (ADC) platform and 2026 strategic priorities at the Biotech Showcase on January 13, 2026, aiming to attract investor interest in its innovative drug development.
- Innovative Drug Development: Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells with its unique PH1 payload, showing significant effects in inducing cancer cell death and activating the immune system in preclinical studies, potentially offering new hope in cancer treatment.
- Clinical Trial Plans: The company has initiated IND enabling studies for AKTX-101, with plans to start its First-In-Human trial by late 2026 or early 2027, marking a significant step in its development and market potential in oncology.
- Multipronged Target Strategy: In addition to AKTX-101, Akari is advancing AKTX-102, an ADC targeting a novel antigen highly relevant in gastrointestinal and lung cancers, showcasing the company's broad pipeline and research capabilities across multiple cancer treatment areas.
See More
Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%
- FDA Approval: Vanda Pharmaceuticals' NEREUS (tradipitant) has received FDA approval for the prevention of motion-induced vomiting in adults, marking a significant advancement in the company's neuropharmaceutical portfolio and is expected to drive future sales growth.
- Stock Surge: Following the FDA approval announcement, Vanda's shares jumped 17.5% to $8.26 in pre-market trading, reflecting strong market confidence in the new drug's potential and likely attracting increased investor interest.
- Market Outlook: The approval of NEREUS not only opens new market opportunities for Vanda Pharmaceuticals but also enhances its market share in the competitive antiemetic drug sector, strengthening the company's long-term profitability prospects.
- Investor Confidence: This FDA approval boosts investor expectations for Vanda's future performance, potentially prompting more institutional investors to reassess their portfolios, further driving the stock price upward.
See More
Akari Therapeutics Advances Novel Antibody Drug Conjugates with Significant Achievements in 2025
- Strategic Milestones: In 2025, Akari Therapeutics made significant strides in the antibody-drug conjugate (ADC) space, particularly with its PH1 payload-based ADC designed to overcome limitations of existing therapies, thereby offering more effective treatment options for cancer patients.
- Lead Program Progress: AKTX-101 achieved notable results in 2025, especially demonstrating strong anti-tumor activity in pancreatic and prostate cancer models, which is expected to lay a solid foundation for clinical trials and enhance the company's competitiveness in cancer treatment.
- GMP Manufacturing Partnership: The collaboration with WuXi XDC marks Akari's transition from a preclinical discovery company to a clinical biotechnology player, ensuring the production of high-quality clinical products to support upcoming trials in 2026.
- Intellectual Property Enhancement: Akari filed three new patents in 2025 to protect the uniqueness of its PH1 payload, further solidifying its market position in the ADC field and providing legal safeguards for future R&D efforts.
See More
